The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
|Articles|April 27, 2022
- April 2022
- Volume 88
- Issue 4
Pet Peeves: April 2022
Brought to you by The Sassy Pharmacist
Advertisement
Spelling Bee Champion
When people spell their name instead of saying John Smith.
Coupon Clippers
When people give you manufacturer coupons at pick up.
Time Crunch
When people ask if we can get the medication ready and they’ll bring the prescription when they come to pick up, “to save time.”
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
over 4 years ago
Case Studies: April 2022over 4 years ago
Generic Product News: April 2022over 4 years ago
OTC Cases: April 2022over 4 years ago
RX Product News: April 2022over 4 years ago
Bijuva From TherapeuticsMDover 4 years ago
Support Individuals Who Abuse Alcoholover 4 years ago
OTC Product News: April 2022over 4 years ago
Services to Improve Therapeutic Outcomes Improve Star Ratingsover 4 years ago
Worldwide Generics Market Will Exceed $507 Billion in 4 YearsAdvertisement
Related to this article
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
2
Understanding Kratom: Pharmacology, Safety, and Regulation
3
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5